CymaBay Completes Enrollment for the RESPONSE Global Phase III Study Evaluating Seladelpar for Patients with Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. announced the completion of enrollment for RESPONSE, a global Phase III study evaluating seladelpar for patients with Primary Biliary Cholangitis.